Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis—A case report

DSpace/Manakin Repository

Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis—A case report

Citable link to this page

 

 
Title: Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis—A case report
Author: Mehrzad, Raman; Nishino, Michiya; Nucera, Carmelo; Dias-Santagata, Dora; Hennessey, James V.; Hasselgren, Per-Olof

Note: Order does not necessarily reflect citation order of authors.

Citation: Mehrzad, Raman, Michiya Nishino, Carmelo Nucera, Dora Dias-Santagata, James V. Hennessey, and Per-Olof Hasselgren. 2017. “Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis—A case report.” International Journal of Surgery Case Reports 38 (1): 180-184. doi:10.1016/j.ijscr.2017.06.067. http://dx.doi.org/10.1016/j.ijscr.2017.06.067.
Full Text & Related Files:
Abstract: Introduction: The follicular variant of papillary thyroid cancer (FVPTC) can be noninvasive or invasive. The invasive form of FVPTC commonly harbors BRAF mutations whereas RAS mutations are more often associated with noninvasive FVPTC and a favorable clinical outcome. Case report A 47-year-old man presented with a metastasis to his right iliac bone as the initial manifestation of a 1.6 cm invasive FVPTC. After total thyroidectomy, the patient underwent additional treatment, including thyroid hormone suppressive treatment to non-detectable TSH levels, repeated courses of radioiodine treatment, external beam radiation, and treatment with the tyrosine kinase inhibitor sorafenib. Despite these therapeutic efforts, the disease progressed with growth of the iliac mass and additional metastatic spread to cervical and lumbar vertebrae causing increasing pain and disability. The patient succumbed to the disease four years after presentation. Retrospective next-generation sequencing of the primary tumor using a pan-cancer targeted mutation and gene fusion panel revealed NRAS Q61K mutation and no other oncogenic alterations. Discussion The study challenges the concept that thyroid neoplasms with isolated RAS mutations are often associated with favorable clinical behavior and may be candidates for conservative management. Conclusion: An isolated RAS mutation in invasive FVPTC may be associated with an aggressive clinical behavior.
Published Version: doi:10.1016/j.ijscr.2017.06.067
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547242/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375169
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters